These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 32740789)

  • 1. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review.
    Rezk MF; Pieper B
    Adv Ther; 2020 Sep; 37(9):3732-3745. PubMed ID: 32740789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases.
    Edwards CJ; Hercogová J; Albrand H; Amiot A
    Expert Opin Biol Ther; 2019 Oct; 19(10):1001-1014. PubMed ID: 31056970
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars and access to biologic therapy in immune-mediated diseases.
    Vázquez-Sánchez R; Navarro-Dávila M; Herráiz ER; Merino-Bohórquez V; Borrás-Blasco J; Onteniente-González A; Iglesias-Lambarri A; Negro-Vega E
    Expert Opin Biol Ther; 2024 Jul; 24(7):647-653. PubMed ID: 38698351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The second decade of anti-TNF-a therapy in clinical practice: new lessons and future directions in the COVID-19 era.
    Evangelatos G; Bamias G; Kitas GD; Kollias G; Sfikakis PP
    Rheumatol Int; 2022 Sep; 42(9):1493-1511. PubMed ID: 35503130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
    Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
    Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Impact of Biosimilars on Chronic Immune-Mediated Inflammatory Diseases.
    Pentek M; Zrubka Z; Gulacsi L
    Curr Pharm Des; 2017; 23(44):6770-6778. PubMed ID: 29189134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know.
    Feldman SR; Bagel J; Namak S
    Am J Med Sci; 2018 May; 355(5):411-417. PubMed ID: 29753369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
    Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
    BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy.
    Pereira R; Lago P; Faria R; Torres T
    Drug Dev Res; 2015 Dec; 76(8):419-27. PubMed ID: 26482111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for treating axial spondyloarthritis.
    Jones A; Ciurtin C; Ismajli M; Leandro M; Sengupta R; Machado PM
    Expert Opin Biol Ther; 2018 Jun; 18(6):641-652. PubMed ID: 29681195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.
    Berns M; Hommes DW
    Expert Opin Investig Drugs; 2016; 25(2):129-43. PubMed ID: 26616476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: A Multidisciplinary Perspective.
    Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
    Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
    Fiorino G; Girolomoni G; Lapadula G; Orlando A; Danese S; Olivieri I;
    Autoimmun Rev; 2014 Jul; 13(7):751-5. PubMed ID: 24657898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: A Value Proposition.
    de Mora F
    BioDrugs; 2019 Aug; 33(4):353-356. PubMed ID: 31175631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.